Retinitis Pigmentosa

Retinitis Pigmentosa (RP) Is a genetically inherited blinding disease afflicting millions in the U.S. and abroad. While there is no recognized treatment for RP, Alfred T. Sapse, MD (r), the President of Stem Cell Pharma considers it as a dual disease, one genetically inherited, that causes the initial retinal damage and one acquired, an autoimmune component due to the recipient immune system reaction to the initial retinal lesions. As such, while the genetic factor cannot be changed, the autoimmune part can be successfully treated and patients can regain a certain measure of lost eyesight. NB. This concept is not recognized by the majority of retinal physicians and researchers. Anti Aging or Aging Control Anti-Aging is as controversial now as it was thousands of years ago. However, what is scientifically proven is that the major cause of aging is the harmone, cortisol, manufactured by the adrenal gland on the top of the kidney.The second aspect are the damages induced by aging, mainly the sclerotic process that goes from brain down to heart, arteries and corpus cavernosum, a major source of ED. Stem Cell Pharma, Inc. has developed a program that is now implemeted by which both cause and effect (cortisol + damages of aging) can be potentailly controlled by an effiective anticortisol (cortisol modulator) program + embryonic stem cells from placenta.


SCPI a Nevada corporation plans to open, subject to Nevada’s legislative approval, a Stem Cell Clinic, the first one of this type in Nevada and in the U S. Its main asset, the stem cell telomerase modulated placenta implant, had been developed by Alfred T. Sapse M.D. (r) who, more than 50 years ago, used placentas, the richest source of stem cells, in the treatment of diseases, some of them with unknown origin, and unknown treatment. Among them Alzheimer’s, Parkinson’s, Aging Diseases, Multiple Sclerosis, Lupus Erythematosus, Strokes, Heart Diseases, Prostate and Breast Cancer, Spinal Cord Injury, Retinitis Pigmentosa, Macular Degeneration, Muscular Dystrophy, and others. At that time Dr. Sapse witnessed with amazement the outstanding results obtained, without knowing that they were due to stem cells, a term that will wait for another 40 years to enter medical vocabulary. At the present time Stem Cell Clinics have opened in many countries of the world, result of growing dissatisfaction of millions needing this type of treatment and unwilling to wait results of many years of research and vague promises that sometimes in the future, treatments would become eventually available. They want stem cells NOW, and there are places where in the stem cells are available NOW. They are the stem cells clinics.

The stem cell treatments used in these clinics, with few exceptions are scientifically sound and the results obtained impressive. The only problem is that all of them are outside the United States and the cost is between $30,000 to $250,000+, and the improvements seem to dissipate 3-4 months later. Even so Americans are traveling abroad to take the treatment, and estimates are that they are spending already about $150 million, with an estimated spending of $1 billion + , in the next 5 years, as patients become aware of the existence of these clinics. Comparing the techniques used by stem cells clinics abroad with the one developed by Dr. Sapse, it would be obvious that our technique is much simpler (one step procedure i.e. amnion stem cell implanting instead of four i.e. collecting blood or others, extracting the stem cells, growing them in tissue cultures and re-injecting them back into the donor), availability (it can be carried out right away instead of waiting for 3- 4 weeks for the stem cells to grow), and cheaper ($5000 versus $30,000+), and most importantly, using only fresh stem cells, not frozen. While awaiting the eventual approval by the Nevada Legislation for our unique stem cell clinic in Las Vegas, Nevada, physicians have already performed 42 stem cell placenta (amnion) implants developed by Dr. Sapse in 28 Multiple Sclerosis (MS) cases, anti-aging (5), Alzheimer’s (3), Muscular Dystrophy (2), Retinitis Pigmentosa (2) and Cerebral Palsy (1), with 70% improvements, some very impressive. Some of these results have been released as News Releases (see news releases).

SCPI is confident that the Nevada legislators after learning the details of the stem cell/placenta implant technique and results already obtainedand becoming aware of the strong demand for this treatment for people desperate to have it, but unable to pay the steep prices asked, would consider and pass the necessary legislative approval. In this respect Nevada has a courageous precedent when in 1977 approved the manufacturing and distribution of Gerovital H3 an anti aging drug previously available only outside the US, in Nevada. Prior to this approval many Americans have traveled in Europe, and spent $10,000 to $12,000 to get this treatment, but once Gerovtial H3 had been approved in Nevada, thousands came to Las Vegas to acquire it for $26 dollars a month, but also enjoyed what Las Vegas had to offer.

SCPI is a privately held S corporation, formed in Las Vegas, Nevada, May 2005. Its capitalization is 10,000,000 (ten million) common shares, $0.001 par value, out of which 3,000,000 (three million) are issued and outstanding. SCPI was formed to carry out research, develop a Stem Cell Clinic (s) and market the stem cell / placenta implant, a product designed by Alfred T. Sapse M.D. (ret) SCPI’S President.